Inozyme Pharma, Inc. Overview
Pro stress-test →Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis. BioMarin Pharmaceutical has agreed to acquire Inozyme Pharma for $4.00 per share in an all-cash transaction valued at approximately $270 million, adding INZ-701, a Phase 3 enzyme replacement therapy.
Strategic Profile
Pro stress-test →INZ-701 targets a rare, serious, and progressive genetic condition that affects blood vessels, soft tissues and bones, with increased cardiovascular mortality risk and severe rickets/osteomalacia in children and adults. The ENERGY 3 pivotal trial for INZ-701 completed enrollment in January 2025, with topline data anticipated in Q1 2026. Analysts project peak annual sales of $400–$600 million by the mid-2030s.
Competitive Landscape
Pro stress-test →ENPP1 Deficiency is an ultra-orphan disease affecting roughly 2,000 patients globally with no approved treatments. INZ-701 positions as potential first-in-disease therapy in a highly specialized rare disease space with limited direct competition. The company is expanding INZ-701 evaluation into additional indications including ABCC6 Deficiency and calciphylaxis.
Industry Context
Inozyme Pharma, Inc. operates in Biopharmaceutical - Rare Diseases / Enzyme Replacement Therapy.
Key facts
Founded: 2015 · Headquarters: Boston, Massachusetts